287 related articles for article (PubMed ID: 12742279)
1. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P; Grind M; Adler J;
J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
[TBL] [Abstract][Full Text] [Related]
2. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
[TBL] [Abstract][Full Text] [Related]
3. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
5. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Olsson SB;
Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
8. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
9. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
10. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
11. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
12. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
13. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
Kulbertus H
Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
[TBL] [Abstract][Full Text] [Related]
14. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
[TBL] [Abstract][Full Text] [Related]
15. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
16. Ximelagatran in prevention of cardiovascular events.
Molckovsky D; Boucher M
Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
[TBL] [Abstract][Full Text] [Related]
17. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Reiffel JA
Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Halperin JL
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
[TBL] [Abstract][Full Text] [Related]
20. New possibilities in anticoagulant management of atrial fibrillation.
Waldo AL
Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
